Abstract
Bilastine, a non-sedating and long-acting second-generation antihistamine, is indicated for the symptomatic treatment of seasonal or perennial allergic rhinoconjunctivitis and urticaria in >90 countries worldwide. It has a favourable pharmacological profile, with a rapid onset of action and sustained efficacy over the 24-h dosing interval period, as well as a lack of CNS and cardiotoxic effects and clinically relevant drug interactions. In clinical trials, the efficacy of bilastine in treating rhinoconjunctivitis and urticaria was greater than that with placebo and generally similar to that of other second-generation antihistamines, and the overall tolerability profile of bilastine was similar to that of placebo.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
